4-(2-氯-1,1,2-三氟乙氧基)苯甲酸 | 405-43-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-氯-1,1,2-三氟乙氧基)苯甲酸
• 英文名称: 4-(1,1,2-trifluoro-2-chloroethoxy)benzoic acid
• 英文别名: 4-(2-chloro-1,1,2-trifluoro-ethoxy)-benzoic acid；4-(2-Chlor-1,1,2-trifluor-aethoxy)-benzoesaeure；4-<2-Chlor-1,1,2-trifluor-aethoxy>-benzoesaeure；4-(1,1,2-Trifluor-2-chlor-ethoxy)-benzoesaeure；4-(2-Chloro-1,1,2-trifluoroethoxy)benzoic acid
• CAS: 405-43-6
• 化学式: C₉H₆ClF₃O₃
• mdl: MFCD00020359
• 分子量: 254.593
• InChiKey: UBPJCHITDRIJEB-UHFFFAOYSA-N

物化性质

• 熔点：
  167-168 °C(Solv: benzene (71-43-2))
• 沸点：
  305.8±42.0 °C(Predicted)
• 密度：
  1.492±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2-氯-1,1,2-三氟乙氧基)苯甲酸 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 反应 96.0h， 生成 4-(2-chloro-1,1,2-trifluoro-ethoxy)-benzoyl chloride
  参考文献：
  名称：

  某些2,5-（氟烷氧基苯基）-1,3,4-恶二唑及其N，N'-二苯甲酰肼前体的合成和杀虫活性

  摘要：

  DOI：

  10.1021/je00053a044
• 作为产物：
  描述：

  4-(1,1,2-三氟-2-氯乙氧基)苯甲酸甲酯 在 氢氧化钾 作用下， 反应 0.17h， 以85.5%的产率得到4-(2-氯-1,1,2-三氟乙氧基)苯甲酸
  参考文献：
  名称：

  Phenols Reactions with 1,1-Difluorodichloroethene, 1,2-Di(fluorochloro)ethene, and Trifluorochloroethene

  摘要：

  Phenols containing in the para-position of the benzene ring substituents of various electronic character add to 1,1-ditluorodichloroethene in acetone in the presence of potassium hydroxide. A similar reaction with 1,2-di(fluorochloro)ethene occurs only in DMF or N,N-dimethylacetamide and is followed by hydrogen chloride elimination. Phenols with electron-donor substituents add to trifluorochloroethene in acetone in the presence of potassium hydroxide, the reaction of phenols with electron-acceptor substituents requires DMF as solvent.

  DOI：

  10.1023/b:rujo.0000010179.88527.27

文献信息

• N,N'-Heptamethylenebis(4-methoxybenzamide)
  申请人：Sterling Drug Inc.

  公开号：US04009208A1

  公开（公告）日：1977-02-22

  4-(Q-O)-4'-R.sub.1 -N,N'-alkylenebis(benzamides), N,N'-alkylenebis(3,4-methylenedioxybenzamides) or N,N'-alkylenebis[4-(lower-alkoxy)benzamides], having endocrinological properties, where Q is lower-alkyl, lower-alkoxyalkyl, lower-alkenyl, halo-lower-alkyl, halo-lower-alkenyl, lower-cycloalkyl, phenyl and BN-(lower-alkyl) where BN is di-(lower-alkyl)amino or a saturated N-heteromonocyclic radical having from five to seven ring atoms and alkylene has at least five carbon atoms between its two connecting linkages and R.sub.1 is Q-O-, hydrogen, lower-alkoxy, lower-alkyl, halo, benzyloxy, hydroxy, di-(lower-alkyl)amino, nitro, amino or trihalomethyl are prepared preferably by reacting the appropriate diamine or N-(aminoalkyl)-benzamide with two or one molar equivalents, respectively, of the appropriate benzoyl halide.

  4-(Q-O)-4'-R.sub.1 -N,N'-烷基亚苯二酰胺，N,N'-烷基亚苯二酰胺或N,N'-烷基亚苯二酰胺[4-(较低烷氧基)苯二酰胺]，具有内分泌学性质，其中Q为较低烷基，较低烷氧基烷基，较低烯基，卤代较低烷基，卤代较低烯基，较低环烷基，苯基和BN-(较低烷基)，其中BN为二(较低烷基)氨基或具有五至七个环原子的饱和N-杂环烷基基团，烷基在其两个连接链之间至少有五个碳原子，R.sub.1为Q-O-，氢，较低烷氧基，较低烷基，卤素，苄氧基，羟基，二(较低烷基)氨基，硝基，氨基或三卤甲基，最好通过将适当的二胺或N-(氨基烷基)-苯二酰胺与相应的苯甲酰卤反应制备两个或一个摩尔当量。
• Current Recommendations for the Treatment of Genital Herpes
  作者：Daniel T. Leung、Stephen L. Sacks

  DOI：10.2165/00003495-200060060-00007

  日期：2000.12

  The incidence of genital herpes continues to increase in epidemic-like fashion. Aciclovir (acyclovir) has been the original gold standard of therapy. The recent addition of famciclovir and valaciclovir as antiherpes drugs has improved convenience as well as the efficacy of treatment. Although aciclovir remains a widely prescribed and reliable drug, its administration schedule falls short of the ease of usage that the newer nucleoside analogues offer, for both episodic and suppressive therapy. Suppression of symptomatic disease and asymptomatic shedding from the genitalia have both become popular approaches, if not the primary targets of antiviral therapy. Knowing that asymptomatic disease leads to most cases of transmission strongly suggests that suppression with antiviral agents could reduce transmission risk in discordant couples. Unfortunately, the role for antivirals in reducing transmission remains to be proven in clinical trials. Neonatal herpes is now successfully treated using aciclovir. Current randomised clinical trials are examining aciclovir and valaciclovir administration, as well as safety and efficacy for post-acute suppressive therapy. Prevention of recurrences in pregnancy is also a topic under investigation, with a view to reducing the medical need for Cesarean section, or alternatively (and far less likely to be accomplished) to protect the neonate. Although resistance is largely limited to the immunocompromised and a change in resistance patterns is not expected, several drugs are available for the treatment of aciclovir-resistant strains of herpes simplex. Foscarnet is the main alternative with proven efficacy in this setting. Unfortunately, administration of foscarnet requires intravenous therapy, although a single anecdote of topical foscarnet efficacy in this setting has been published. Alternatives include cidofovir gel, which is not commercially available but can be formulated locally from the intravenous preparation. Less effective alternatives include trifluridine and interferon. Future possibilities for treatment of genital herpes include a microparticle-based controlled-release formulation of aciclovir and resiquimod (VML-600; R-848). The search for an effective therapeutic vaccine for genital herpes has not been successful to date, although a live virus glycoprotein H-deficient (DISC) vaccine is currently in clinical trials. Recent data suggest that seronegative women are protected (albeit, not fully) by a glycoprotein D recombinant vaccine with adjuvant. Despite the established safety and convenience of current treatment options, better suppressive options and topical treatment options are much needed. Studies using existing agents as potential tools to avoid Cesarean section, or transmission to neonate or partner are ongoing. Both vaccines and antivirals may eventually play a role in prevention of infection.

  生殖器疱疹的发病率继续以流行病的方式增加。阿昔洛韦（aciclovir）一直是治疗的原始金标准。近期，法莫昔洛韦（famciclovir）和瓦尔阿昔洛韦（valaciclovir）作为抗疱疹药物的加入提升了治疗的便利性和疗效。尽管阿昔洛韦依然是一种广泛处方和可靠的药物，但其给药方案不如新一代核苷类似物在发作性和抑制性治疗方面的使用方便。抑制有症状的疾病和无症状的生殖器病毒排泄已成为流行的治疗方法，甚至成为抗病毒治疗的主要目标。考虑到无症状疾病是大多数传播案例的根源，这强烈表明使用抗病毒药物进行抑制治疗可能会降低不一致伴侣之间的传播风险。不幸的是，目前尚需临床试验证实抗病毒药物在减少传播中的作用。新生儿疱疹目前已成功使用阿昔洛韦进行治疗。当前的随机临床试验正在研究阿昔洛韦和瓦尔阿昔洛韦的给药，及其在急性后抑制治疗中的安全性和疗效。预防妊娠期间复发也是一个正在研究的话题，旨在减少剖宫产的医疗需求，或者（较不可能实现的）保护新生儿。尽管抗药性主要限于免疫系统受损的患者，且抗药性模式不太可能发生变化，但目前有几种药物可用于治疗阿昔洛韦耐药型单纯疱疹。福赛那特（foscarnet）是这一领域主要的替代药物，并已证明其有效性。不幸的是，福赛那特的给药需要通过静脉治疗，尽管已经有关于局部福赛那特在此情况下有效性的单个案例报告。其他替代品包括cidofovir凝胶，虽然市面上没有供应，但可以通过静脉制剂在当地制备。不太有效的替代药物包括三氟尿嘧啶和干扰素。未来生殖器疱疹的治疗可能包括基于微球的阿昔洛韦和瑞克莫德的控释制剂（VML-600；R-848）。迄今为止寻找有效的生殖器疱疹治疗疫苗尚未成功，尽管一种缺乏糖蛋白H的活病毒疫苗（DISC）目前在进行临床试验。最新数据显示，阴性血清女性在一定程度上受到含佐剂的糖蛋白D重组疫苗的保护（尽管并非完全）。尽管现有治疗选项已确立其安全性和便利性，但仍迫切需要更好的抑制选项和局部治疗方案。目前有研究正在使用现有药物作为潜在工具，以避免剖宫产或向新生儿或伴侣传播感染。疫苗和抗病毒药物最终可能在预防感染中发挥作用。
• Lichtenberger,J.; Rusch,R.E., Bulletin de la Societe Chimique de France, 1962, p. 254 - 262
  作者：Lichtenberger,J.、Rusch,R.E.

  DOI：——

  日期：——
• Lichtenberger,J.; Rusch,R.E., Bulletin de la Societe Chimique de France, 1962, p. 325 - 329
  作者：Lichtenberger,J.、Rusch,R.E.

  DOI：——

  日期：——
• IDOUX, JOHN P.;GIBBS-REIN, KATHLEEN S.;GUPTON, JOHN T.;CUNNINGHAM, GLENN +, J. CHEM. AND ENG. DATA, 33,(1988) N 3, 385-388
  作者：IDOUX, JOHN P.、GIBBS-REIN, KATHLEEN S.、GUPTON, JOHN T.、CUNNINGHAM, GLENN +

  DOI：——

  日期：——